Cargando…
Head to head randomized trial of two decision aids for prostate cancer
BACKGROUND: While many studies have tested the impact of a decision aid (DA) compared to not receiving any DA, far fewer have tested how different types of DAs affect key outcomes such as treatment choice, patient–provider communication, or decision process/satisfaction. This study tested the impact...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117645/ https://www.ncbi.nlm.nih.gov/pubmed/33980208 http://dx.doi.org/10.1186/s12911-021-01505-x |
_version_ | 1783691623873380352 |
---|---|
author | Fagerlin, Angela Holmes-Rovner, Margaret Hofer, Timothy P. Rovner, David Alexander, Stewart C. Knight, Sara J. Ling, Bruce S. A.Tulsky, James Wei, John T. Hafez, Khaled Kahn, Valerie C. Connochie, Daniel Gingrich, Jeffery Ubel, Peter A. |
author_facet | Fagerlin, Angela Holmes-Rovner, Margaret Hofer, Timothy P. Rovner, David Alexander, Stewart C. Knight, Sara J. Ling, Bruce S. A.Tulsky, James Wei, John T. Hafez, Khaled Kahn, Valerie C. Connochie, Daniel Gingrich, Jeffery Ubel, Peter A. |
author_sort | Fagerlin, Angela |
collection | PubMed |
description | BACKGROUND: While many studies have tested the impact of a decision aid (DA) compared to not receiving any DA, far fewer have tested how different types of DAs affect key outcomes such as treatment choice, patient–provider communication, or decision process/satisfaction. This study tested the impact of a complex medical oriented DA compared to a more simplistic decision aid designed to encourage shared decision making in men with clinically localized prostate cancer. METHODS: 1028 men at 4 VA hospitals were recruited after a scheduled prostate biopsy. Participants completed baseline measures and were randomized to receive either a simple or complex DA. Participants were men with clinically localized cancer (N = 285) by biopsy and who completed a baseline survey. Survey measures: baseline (biopsy); immediately prior to seeing the physician for biopsy results (pre- encounter); one week following the physician visit (post-encounter). Outcome measures included treatment preference and treatment received, knowledge, preference for shared decision making, decision making process, and patients’ use and satisfaction with the DA. RESULTS: Participants who received the simple DA had greater interest in shared decision making after reading the DA (p = 0.03), found the DA more helpful (p’s < 0.01) and were more likely to be considering watchful waiting (p = 0.03) compared to those receiving the complex DA at Time 2. While these differences were present before patients saw their urologists, there was no difference between groups in the treatment patients received. CONCLUSIONS: The simple DA led to increased desire for shared decision making and for less aggressive treatment. However, these differences disappeared following the physician visit, which appeared to change patients’ treatment preferences. Trial registration This trial was pre-registered prior to recruitment of participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12911-021-01505-x. |
format | Online Article Text |
id | pubmed-8117645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81176452021-05-17 Head to head randomized trial of two decision aids for prostate cancer Fagerlin, Angela Holmes-Rovner, Margaret Hofer, Timothy P. Rovner, David Alexander, Stewart C. Knight, Sara J. Ling, Bruce S. A.Tulsky, James Wei, John T. Hafez, Khaled Kahn, Valerie C. Connochie, Daniel Gingrich, Jeffery Ubel, Peter A. BMC Med Inform Decis Mak Research Article BACKGROUND: While many studies have tested the impact of a decision aid (DA) compared to not receiving any DA, far fewer have tested how different types of DAs affect key outcomes such as treatment choice, patient–provider communication, or decision process/satisfaction. This study tested the impact of a complex medical oriented DA compared to a more simplistic decision aid designed to encourage shared decision making in men with clinically localized prostate cancer. METHODS: 1028 men at 4 VA hospitals were recruited after a scheduled prostate biopsy. Participants completed baseline measures and were randomized to receive either a simple or complex DA. Participants were men with clinically localized cancer (N = 285) by biopsy and who completed a baseline survey. Survey measures: baseline (biopsy); immediately prior to seeing the physician for biopsy results (pre- encounter); one week following the physician visit (post-encounter). Outcome measures included treatment preference and treatment received, knowledge, preference for shared decision making, decision making process, and patients’ use and satisfaction with the DA. RESULTS: Participants who received the simple DA had greater interest in shared decision making after reading the DA (p = 0.03), found the DA more helpful (p’s < 0.01) and were more likely to be considering watchful waiting (p = 0.03) compared to those receiving the complex DA at Time 2. While these differences were present before patients saw their urologists, there was no difference between groups in the treatment patients received. CONCLUSIONS: The simple DA led to increased desire for shared decision making and for less aggressive treatment. However, these differences disappeared following the physician visit, which appeared to change patients’ treatment preferences. Trial registration This trial was pre-registered prior to recruitment of participants. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12911-021-01505-x. BioMed Central 2021-05-12 /pmc/articles/PMC8117645/ /pubmed/33980208 http://dx.doi.org/10.1186/s12911-021-01505-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Fagerlin, Angela Holmes-Rovner, Margaret Hofer, Timothy P. Rovner, David Alexander, Stewart C. Knight, Sara J. Ling, Bruce S. A.Tulsky, James Wei, John T. Hafez, Khaled Kahn, Valerie C. Connochie, Daniel Gingrich, Jeffery Ubel, Peter A. Head to head randomized trial of two decision aids for prostate cancer |
title | Head to head randomized trial of two decision aids for prostate cancer |
title_full | Head to head randomized trial of two decision aids for prostate cancer |
title_fullStr | Head to head randomized trial of two decision aids for prostate cancer |
title_full_unstemmed | Head to head randomized trial of two decision aids for prostate cancer |
title_short | Head to head randomized trial of two decision aids for prostate cancer |
title_sort | head to head randomized trial of two decision aids for prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117645/ https://www.ncbi.nlm.nih.gov/pubmed/33980208 http://dx.doi.org/10.1186/s12911-021-01505-x |
work_keys_str_mv | AT fagerlinangela headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT holmesrovnermargaret headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT hofertimothyp headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT rovnerdavid headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT alexanderstewartc headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT knightsaraj headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT lingbruces headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT atulskyjames headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT weijohnt headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT hafezkhaled headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT kahnvaleriec headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT connochiedaniel headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT gingrichjeffery headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer AT ubelpetera headtoheadrandomizedtrialoftwodecisionaidsforprostatecancer |